Skip to content

Infiltration in the Region of the Palatine Ganglion Spheno by Ropivacaine on Postoperative Pain

Impact of Infiltration in the Region of the Palatine Ganglion Spheno by Ropivacaine on Postoperative Pain in the Setting of Endoscopic Sinonasal Surgery.

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02821169
Acronym
ROPI_POSTOP
Enrollment
184
Registered
2016-07-01
Start date
2015-04-30
Completion date
2019-06-30
Last updated
2025-12-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

sinus surgery, sphenopalatin ganglion, ropivacaine, local anesthesia

Brief summary

Endoscopic sinus surgery (ESS) is a prevalent surgical procedure. It is required in many chronic rhinosinusitis for whom the medical treatment failed. In order to improve the postoperative management of patients treated with ESS, we aim to assess the analgesic action of local injection of ropivacaine in the nasal fossa.

Detailed description

A prospective randomized double blind placebo controlled study was designed. Local injection of ropivacaine or placebo was conducted at the end of the surgical procedure in both nasal fossa through endoscopic view in the sphenopalatine region. Pain was measured in the postoperative course with visual analogic scale in the recovery room and the rhinologic department.

Interventions

DRUGropivacaine

injection of 4mL of ropivacaine in the sphenopalatine area through an endoscopic approach

injection of 4 mL of saline solution in the sphenopalatine area through an endoscopic approach

Sponsors

University Hospital, Lille
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* patients requiring endoscopic sinus surgery * ASA score 1 or 2 * patients with health care insurance * approved consent

Exclusion criteria

* any sinonasal malignant tumor * renal failure, hepatic disorder, respiratory deficiency, cardiovascular diseases * neurologic disorders * alcohol or drugs addiction * preoperative facial pain from an extranasal origin * coagulation disorders * antidepressive treatment

Design outcomes

Primary

MeasureTime frameDescription
Visual analog scaleat the 2 postoperative hoursMeasure the intensity pain, in the group treated with Ropivacaine.

Secondary

MeasureTime frameDescription
Analgesics consumption orallyduring the 7 days post-surgerypatient-controlled administration
Administration of analgesics by parenteral routeat the 2 postoperative hourspatient-controlled administration
Visual analog scale for the intensity postoperative painat the 4 and at the 6 postoperative hourspatient-controlled administration
Visual analog scale for the during postoperative painAt Morning and evening between the 1 and 7 days post surgeryself-assessment by the patient at home on the information collection book

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026